SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Benjamin Franklin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBenjamin Franklin
Date of birth1706-01-17
IdentifiersMRN HR-EN004-SYN-TD; SSN (made up) 000-04-3318
Document date1782-09-14
AuthorLydia Penhallow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Gout, stone prevention, kidney, and blood pressure review at about six months. [S]

History of Present Illness

Mr. Franklin returns about six months after starting urate-lowering therapy. He had one gout flare, in the left knee ten weeks ago, treated with five days of prednisone; the knee culture grew nothing, and he has had no flare since. The potassium and urate checks planned for two to five weeks after his last visit were not drawn until that sick visit, at seven weeks. He takes allopurinol 300 mg, colchicine 0.6 mg, losartan, atorvastatin, and potassium citrate. His home jug shows about 2.3 L of urine a day. His home blood pressure averages 128/76. He voids well, with nocturia once. He walks 30 minutes most days and has lost 3 kg. [S]

ElementDetail
Interval historyOne left knee flare ten weeks ago, crystal-proven and culture-negative; none since
Missed checksPotassium and urate planned for 2 to 5 weeks were drawn at the sick visit at seven weeks
Urine outputAbout 2.3 L a day by measuring jug
Home blood pressureAverage 128/76 mmHg
Medication toleranceNo rash, diarrhea, muscle aches, or stomach upset from potassium citrate
WeightDown 3 kg since March

Review of Systems

SystemResultFinding
MusculoskeletalNegativeNo joint pain or swelling since the knee flare; no muscle aches
GenitourinaryNegativeGood stream, nocturia once, no blood in the urine
GastrointestinalNegativeNo nausea or abdominal pain on potassium citrate
NeurologicalNegativeNo dizziness on standing

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1775-05-06 to 1782-03-02stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1782-03-02activeS
Allopurinol 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1782-03-02 to 1782-03-30completedS
Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth dailyTwo tablets by mouth dailyOral route1782-03-30 to 1782-05-18completedS
Allopurinol 300 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1782-05-18activeS
Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxisOne tablet by mouth dailyOral route1782-03-02 to 1782-09-14completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route1782-03-02activeS
Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgeryOne capsule by mouth at bedtimeOral route1782-03-30 to 1782-04-20completedS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1782-03-30activeS
Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route1782-05-18activeS
Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for 5 daysTwo tablets by mouth each morning for 5 days, with foodOral route1782-07-06 to 1782-07-10completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1782-09-14Body height175cmS
1782-09-14Body weight93.2kgS
1782-09-14Body mass index (BMI) [Ratio]30.4kg/m2S
1782-09-14Systolic blood pressure128mm[Hg]S
1782-09-14Diastolic blood pressure76mm[Hg]S
1782-09-14Heart rate68/minS
1782-09-14Respiratory rate14/minS
1782-09-14Body temperature36.6CelS
1782-09-14Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1782-09-14Urate [Mass/volume] in Serum or Plasma5.4mg/dL3.5-7.2 mg/dLNormalS
1782-09-14Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1782-09-14Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1782-09-14Carbon dioxide, total [Moles/volume] in Serum or Plasma26mmol/L22-29 mmol/LNormalS
1782-09-14Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL8-23 mg/dLNormalS
1782-09-14Creatinine [Mass/volume] in Serum or Plasma1.32mg/dL0.74-1.35 mg/dLNormalS
1782-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1777)/1.73 sq M56mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
1782-09-14Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
1782-09-14pH of Urine6.3[pH]4.5-8 [pH]NormalS
1782-09-14US Urinary bladder Volume post void30mL<=100 mLNormalS
1782-09-14International Prostate Symptom Score [IPSS]5{score}S

Physical Exam

Vital signs recorded on 1782-09-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell
JointsNo synovitis or tophi; left knee without effusion
CardiovascularRegular rhythm; no edema; pedal pulses palpable
AbdomenNo suprapubic tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented goutactiveconfirmed M1A.0710S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D).
Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stoneresolvedconfirmed N21.0S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known.
Chronic kidney disease stage G3a A1activeconfirmed N18.31S — Synthetic diagnosis; no measure of kidney function from his lifetime exists.
Essential hypertensionactiveconfirmed I10S — Synthetic diagnosis; no blood pressure from his lifetime exists.
Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resectionactiveconfirmed N40.1S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented.
Acute gout flare of the left knee, crystal-proven, during urate-lowering titration; resolvedresolvedconfirmed M10.062S — Synthetic flare at an unscheduled visit; flares are common in the first months of urate-lowering therapy. It does not echo a dated historical attack.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySerum urateEvery 2 to 5 weeks while titrating; every 6 months once at targetCompleted today5.4 mg/dL on allopurinol 300 mg: at target
LaboratorySerum urate 2 to 5 weeks after raising allopurinol to 300 mgOnce after each dose changeDeferredNot drawn in the window, a deviation from the protocol; the first value came at the July flare visit at seven weeks (5.9 mg/dL, unreliable during a flare). No change in management resulted, and today's 5.4 confirms the target. Corrective action: the standing order now prints at each visit
LaboratoryPotassium 2 to 4 weeks after starting potassium citrate with losartan in chronic kidney diseaseOnce after starting; then periodicallyDeferredNot drawn in the window, a deviation from the protocol; first checked at the July sick visit at seven weeks (4.7 mmol/L). No harm: potassium 4.6 today. Corrective action: potassium is added to the standing order whenever a potassium-raising drug is started
LaboratoryMetabolic panelEvery 6 months on an ARB; with each eGFR drawCompleted todayPotassium 4.6 mmol/L, bicarbonate 26 mmol/L, creatinine 1.32 mg/dL, eGFR 56
LaboratoryUrine pH on alkalinizationWith each follow-up on potassium citrateCompleted today6.3, within the goal
Medication safetyFlare prophylaxis3 to 6 months, longer if flares continueCompleted todayStopped today after more than six months; urate at target and no flare for ten weeks
ExaminationOffice and home blood pressureEvery visitCompleted today128/76 mmHg office and home
ExaminationPeripheral pulsesEvery 2 to 3 years at 65 or olderCompleted todayPedal pulses palpable; no claudication
SurveyIPSSEvery follow-up; 1, 3, 6, and 12 months after a procedureCompleted today5
ExaminationPost-void residualPost-procedural follow-upCompleted today30 mL
SurveyThree-month post-procedural urologic checkAbout 3 months after the procedureDeferredNo separate visit was held at three months, a deviation from the follow-up schedule; urinary symptoms were reviewed and negative at the July sick visit. No harm: IPSS and residual are normal today
LaboratoryeGFR, urine albumin-creatinine ratio, hemoglobin, and KFREYearly at G3a A1Up to dateDone in March (KFRE 0.2 percent at 2 years and 0.6 percent at 5 years, well below referral thresholds); due again next March
LaboratoryCalcium, phosphate, PTH, and vitamin DBaseline at G3a, then every 6 to 12 monthsDueNormal in March; due next March
LaboratoryLipid panelOnce at CKD diagnosis (KDIGO); yearly in the CMID hypertension scheduleNot indicatedOn atorvastatin for kidney disease; KDIGO advises no routine repeat lipid testing
Medication safetyMedication review for NSAIDs and drug interactionsEvery visitCompleted todayNo NSAIDs; colchicine with atorvastatin caused no muscle symptoms, and colchicine stops today
Medication safetyVaccination statusYearlyDueInfluenza and RSV vaccines planned at next month's wellness visit
Self-managementFluids, diet, alcohol, weight, and activityEvery visitCompleted todayAbout 2.3 L of urine a day; one glass of wine on most evenings; 3 kg weight loss; walking 30 minutes most days

Goal progress:

Guideline basis: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019); EAU Guidelines on Urolithiasis (including bladder stones) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026)

Follow-up: Annual wellness visit next month. Serum urate, urine pH, and yearly kidney tests in six months. Next scheduled visit 1782-10-19: subsequent annual wellness visit. [S]